Member Info for Northorsouth

Mark Davis CEO
We are quietly assured that that is the very best fast lateral stream diagnostic on this planet and the UK doesn’t need it. It additionally prices a fourth of the worth of the Innova test.

https://uk.newschant.com/business/covid-test-maker-mologic-set-to-sue-government-over-stonewalling/

https://www.telegraph.co.uk/business/2021/06/14/covid-test-maker-mologic-set-sue-government-stonewalling/

Behind paywall.

Hilarious, they obviously read tweets from ODX, AVCT, ABDX & NCYT.
They know the best is coming & made in UK.

Americans are told to STOP using rapid Covid test UK has spent £2.8billion on in hopes of lifting lockdown because manufacturer of 15-minute swab has LIED about how good they are

https://www.dailymail.co.uk/news/article-9676137/amp/Americans-told-STOP-using-rapid-Covid-test-manufacturer-LIED-good-are.html?__twitter_impression=true

The sun is shining & ODX are awake.

https://twitter.com/OmegaDiagnostic/status/1399634558547632128

Thanks Tricky for the updates.

https://news.sky.com/story/revealed-countries-who-will-accept-nhs-covid-app-as-a-vaccine-passport-12318506

just seen your post, just as i posted

Investors in diagnostic testing firms such as Omega Diagnostics and Avacta were provided with a timely boost in sentiment from the world’s largest rapid COVID-19 test manufacturer today.

www.sharebuyers.co.uk/shares/lateral-flow-tests-touted-to-be-in-demand-for-many-years/

ODX need to learn a few lessons from them!!!

Im still holding strong & ingnoring all the noise.

https://twitter.com/Abingdon_Health/status/1397184786481942536

https://twitter.com/Abingdon_Health/status/1396788671672688640

ODX On Twitter.

https://twitter.com/OmegaDiagnostic/status/1395318618859126784

Abbingdon have been tweeting quite a bit lately. Their twitter has a positive impact on their share price.

https://twitter.com/Abingdon_Health?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

From Mologic tweet.
To clarify, this tweet refers to the expected next steps as described in Avacta’s RNS - completing the necessary assessment of the product from our manufacturing partner Global Access Diagnostics, including stability testing, that will complete the technical file for CE marking.

Thanks for sharing

News due by end of April.
Let’s hope we get some details on manufacturers & licenses.

Paraytec will now progress to a prospective clinical validation with a larger number of patient samples and seek to obtain a CE mark for the test. Depending on location, the prospective clinical trial (where individual patient outcomes are monitored over time) is expected to take two months to complete and a further update is expected to be made by the end of April 2021. As previously stated, Paraytec are seeking manufacturers and licensees to take the product to the global market, with first product manufacture expected in six months, subject to regulatory approval.

https://www.abc19.com/uk-rtc-antibody-certificate-smartphone-app/

It's all happening behind the scenes.

I’m sure we all remember ODX named in the press as a government manufacturer for LFT’s, then that RNS landed & nearly everyone was dismayed at how cautious Colin was in his wording.
So many slated him & the share price dropped.

We all know dealing with the government has its ups & downs. When ODX announced the ABC Antibody LFT selling to the government, we thought the price would rocket, but the orders didn’t materialise.

It’s a good thing that ODX are now being cautious & not reliable just on manufacturing for the government. Great things are happening behind the scenes & we are all going to hear news very soon. (Even if the wait seems forever)

I didn’t have shares but I feel for the holders of NCYT who lost money yesterday.

I’m a LTH who reads this BB daily, I have faith ODX will delivery what they say they will.
Good things come to those who wait.
Keep the Faith, and GLA

Thanks Visainn. Appreciate the updates from L2

https://goodlawproject.org/update/government-in-breach-of-the-law/

Government admitted it had breached the law by persistently failing to publish details of COVID-19 contracts.